Imunofan, nasal spray 45 µg/dose bottle 40 doses

Composition

Active ingredient: imunofan-50 mcg/1 dose Auxiliary substances: sodium chloride, benzalkonium chloride, glycine, sodium edetate (trilon B), purified water.

Pharmacological action

Imunofan is a detoxifying, hepatoprotective, antioxidant, and immunomodulatory agent.

Pharmacodynamics

The drug has an immunoregulatory, detoxifying, hepatoprotective effect and causes inactivation of free radical and peroxide compounds. It corrects the state of the immune system, restores the balance of redox – antioxidant reactions of the body, and helps to overcome multiple drug resistance of tumor cells mediated by proteins of the cell’s transmembrane transport pump.

The effect of the drug begins to develop within 2-3 hours (fast phase) and lasts up to 4 months (medium and slow phases).

During the rapid phase (duration — up to 2-3 days), the detoxification effect is primarily manifested — the body’s antioxidant defense is enhanced due to stimulation of the production of ceruloplasmin, lactoferrin, and catalase activity; the drug normalizes lipid peroxidation, inhibits the breakdown of cell membrane phospholipids and arachidonic acid synthesis, followed by a decrease in blood cholesterol levels and the production of inflammatory mediators.

In case of toxic and infectious liver damage, the drug prevents cytolysis, reduces the activity of transaminases and the level of bilirubin in the blood serum.

During the middle phase (starting in 2-3 days, lasting up to 7-10 days), phagocytosis reactions and the death of intracellular bacteria and viruses increase.

During the slow phase (begins to develop on 7-10 days, duration up to 4 months), the immunoregulatory effect of Imunofan® is manifested — restoration of impaired cellular and humoral immunity indicators. During this period, normalization of the immunoregulatory index is observed, and an increase in the production of specific antibodies is noted.

The effect of the drug on the production of specific antiviral and antibacterial antibodies is equivalent to the effect of therapeutic vaccines. Unlike the latter, the drug does not significantly affect the production of reagin antibodies of the IgE class and does not enhance the immediate hypersensitivity reaction; Imunofan® stimulates the formation of IgA in its congenital insufficiency.

Imunofan ® effectively suppresses multiple drug resistance of tumor cells and increases their sensitivity to the action of chemotherapeutic drugs.

Indications

• For adults and children over 2 years of age (prevention and treatment):
• immunodeficiency and toxic conditions;
• acute and chronic infectious and inflammatory diseases.

Use during pregnancy and lactation

Due to insufficient knowledge, it should be used with caution during pregnancy and lactation.

Contraindications

Hypersensitivity; children under 2 years of age.

Side effects

Possible: individual intolerance, allergic reactions.

Interaction

Increases the effectiveness of other types of drug therapy: the use of imunofan helps to overcome resistance to glucocorticoid therapy.

use of the drug is possible in combination with anti-inflammatory steroid and non-steroidal anti-inflammatory drugs.

How to take, course of use and dosage

Intranasally. When using, the bottle should be held vertically, with the spray bottle facing up.

In 1 dose of the drug contains 50 mcg of imunofan. The daily dose should not exceed 200 mcg.

• In the complex therapy of acute and chronic infectious and inflammatory diseases accompanied by symptoms of intoxication and immunodeficiency

  Assign 1 dose (50 mcg) in each nasal passage 2 times a day, daily for 10-15 days.

• For opportunistic infections (cytomegalovirus and herpetic infection, toxoplasmosis, chlamydia, pneumocystis, cryptosporidiosis)

  1 dose (50 mcg) in each nasal passage 2 times a day, daily, the course of treatment is 10-15 days. If necessary, it is possible to repeat the course in 2-4 weeks.

• For chronic viral hepatitis and chronic brucellosis

  1 dose (50 mcg) in each nasal passage 1 time a day, daily, the course of treatment is 10-15 days, to prevent relapse, repeated courses should be carried out after 4-6 months.

• In the treatment regimen for patients with HIV infection

  1 dose (50 mcg) in each nasal passage 1 time a day, daily, for 10-15 days. If necessary, it is possible to repeat the course in 2-4 weeks.

• In the treatment of cancer patients in the scheme of radical combined treatment (chemo-radiation therapy and surgery)

  1 dose (50 mcg) in each nasal passage once a day, daily, for 8-10 days before chemo-radiation therapy and surgery, followed by continuation of the course throughout the entire treatment period.

• In patients with advanced tumor process (stage III-IV) of various localization in terms of complex or symptomatic therapy

  1 dose (50 mcg) in each nasal passage 1 time a day, daily, for 8-10 days. If necessary and the presence of pronounced toxicosis phenomena, it is recommended to repeat the course.

Special instructions

As a result of activation of phagocytosis, a short-term exacerbation of foci of chronic inflammation, supported by the persistence of viral or bacterial antigens, is possible.

Product form

nasal spray

Storage conditions

The drug is stored in a place protected from light at a temperature of 2°C to 10°C, out of the reach of children. It is not recommended to use the drug after the expiration date indicated on the package.

Shelf life

2 years

Active ingredient

Arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine

Conditions of release from pharmacies

By prescription

Dosage Form

Spray nasal